Syndax Pharmaceuticals (SNDX) EPS (Weighted Average and Diluted) (2021 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly EPS (Weighted Average and Diluted) of -$0.48 in Q1 2026, up 38.46% quarter-over-quarter from -$0.78 in Q4 2025, and up 51.02% on a YoY basis from -$0.32 in Q1 2025.
Syndax Pharmaceuticals (SNDX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Syndax Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.48 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 51.02% year-over-year to -$0.48; the TTM figure through Mar 2026 stood at -$2.79 (up 27.53% YoY), while the FY2025 annual figure was -$3.29, up 11.56% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.48 for Q1 2026 at Syndax Pharmaceuticals, up from -$0.78 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.48 in Q1 2026 to a low of -$1.09 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.76 across 5 years, with a median of -$0.73 in 2023.
- The sharpest annual moves came in 2022 and 2026: EPS (Weighted Average and Diluted) plunged 133.7% in 2022, then surged 51.02% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.62 in 2022, then sank by 62.9% to -$1.01 in 2023, then declined by 7.92% to -$1.09 in 2024, then advanced by 28.44% to -$0.78 in 2025, then soared by 38.46% to -$0.48 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.48 (Q1 2026), -$0.78 (Q4 2025), and -$0.7 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn | -0.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.48 |
| Dec 31, 2025 | -0.78 |
| Sep 30, 2025 | -0.70 |
| Jun 30, 2025 | -0.83 |
| Mar 31, 2025 | -0.98 |
| Dec 31, 2024 | -1.09 |
| Sep 30, 2024 | -0.98 |
| Jun 30, 2024 | -0.80 |
| Mar 31, 2024 | -0.85 |
| Dec 31, 2023 | -1.01 |
| Sep 30, 2023 | -0.73 |
| Jun 30, 2023 | -0.64 |
| Mar 31, 2023 | -0.59 |
| Dec 31, 2022 | -0.62 |
| Sep 30, 2022 | -0.58 |
| Jun 30, 2022 | -0.62 |
| Mar 31, 2022 | -0.63 |
| Dec 31, 2021 | 1.84 |
| Sep 30, 2021 | -0.40 |
| Jun 30, 2021 | -0.44 |